ContraFect (CFRX) Provides Update from the Futility Analysis of the Phase 3 DISRUPT Study of Exebacase streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
YONKERS, N.Y., Aug. 15, 2022 ContraFect Corporation , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents , including lysins and amurin. | August 15, 2022